The FDA has granted Priority Review for AstraZeneca’s (NASDAQ:AZN) Farxiga (dapagliflozin) for the treatment of new or worsening chronic kidney disease (CKD) in adults with and without type 2 diabetes (T2D). Agency's action date will be during the second quarter of 2021.